

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

August 24, 2009

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

ARCA biopharma, Inc., formerly Nuvelo, Inc.

File No. 000-22873- CF#23952

ARCA biopharma, Inc., formerly Nuvelo, Inc., submitted an application under Rule 24b-2 requesting an extension of a prior grant of confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on August 14, 2003.

Based on representations by ARCA biopharma, Inc., formerly Nuvelo, Inc., that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1	through August 14, 2013
Exhibit 10.2	through August 14, 2013

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Christian Windsor
Special Counsel